[1]王和林,李明瑛,韩　伟,等.芪甲利肺胶囊辅助治疗复治肺结核合并2型糖尿病的疗效及T淋巴细胞亚群的变化[J].新乡医学院学报,2016,33(10):922-926.[doi:10.7683/xxyxyxb.2016.10.024]
　WANG He-lin,LI Ming-ying,HAN Wei,et al.Auxiliary curative effect of Qijialifei capsule for the treatment of recurrent pulmonary tuberculosis with type 2 diabetes and the changes of T lymphocyte subsets[J].Journal of Xinxiang Medical University,2016,33(10):922-926.[doi:10.7683/xxyxyxb.2016.10.024]
点击复制

芪甲利肺胶囊辅助治疗复治肺结核合并2型糖尿病的疗效及T淋巴细胞亚群的变化
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
33
期数:
2016年10
页码:
922-926
栏目:
临床研究
出版日期:
2016-10-05

文章信息/Info

Title:
Auxiliary curative effect of Qijialifei capsule for the treatment of recurrent pulmonary tuberculosis with type 2 diabetes and the changes of T lymphocyte subsets
作者:
王和林1; 李明瑛2; 韩　伟1; 肖志坚1
（1.新乡医学院第一附属医院结核内科二病区，河南　卫辉　453100；2.新乡医学院第一附属医院结核内科四病区，河南　卫辉　453100）
Author(s):
WANG He-lin1; LI Ming-ying2; HAN Wei1; XIAO Zhi-jian1
(1.The Second Department of Tuberculosis,the First Affiliated Hospital of Xinxiang Medical University,Weihui 453100,Henan Province,China;2.The Fourth Department of Tuberculosis,the First Affiliated Hospital of Xinxiang Medical University,Weihui 453100,Henan Province,China)
关键词:
肺结核; 复治; 糖尿病; 中成药; 抗结核药; T淋巴细胞亚群
Keywords:
tuberculosis; retreatment; diabetes; Chinese patent medicine; anti tuberculosis drugs; T lymphocyte subsets
分类号:
R521R587.1
DOI:
10.7683/xxyxyxb.2016.10.024
文献标志码:
A
摘要:
目的　探讨芪甲利肺胶囊辅助治疗复治肺结核合并2型糖尿病患者的疗效及T淋巴细胞亚群的变化。方法　将280例经细菌学确诊的复治肺结核合并2型糖尿病患者按入院先后顺序随机分为观察组和对照组，每组140例。2组患者均应用3HRZES/9HRE(H：异烟肼，R：利福平，Z：吡嗪酰胺，E：乙胺丁醇，S：链霉素)方案抗结核治疗，观察组患者在此基础上加用芪甲利肺胶囊辅助治疗，每次3粒，口服，每日3次，疗程8个月。比较2组患者痰菌转阴情况、病灶及空洞变化情况、中医证候疗效及细胞免疫功能的差异。结果　观察组患者强化期治疗结束时和疗程结束时痰菌阴转率分别为73.72％(101/137)、91.24％(125/137)，对照组患者分别为57.97％(80/138)、80.43％(111/138)，观察组患者强化期治疗结束时和疗程结束时痰菌阴转率均高于对照组 (P<0.05)。观察组患者强化期结束时和疗程结束时病灶吸收的显效率分别为68.62％(94/137)、87.59％(120/137)，对照组患者分别为45.65％(63/138)、69.57％(96/138)，观察组患者强化期结束时和疗程结束时病灶吸收的显效率均高于对照组 (P<0.05)。观察组患者强化期结束时和疗程结束时空洞闭合率分别为21.9％(30/137)、54.01％(74/137)，对照组患者分别为10.87％(15/138)、28.26％(39/138)，观察组患者强化期结束时和疗程结束时空洞闭合率均高于对照组 (P<0.05)。疗程结束时观察组和对照组患者中医证候疗效总有效率分别为89.78％(123/137)、79.71％(110/138)，观察组患者中医证候疗效总有效率高于对照组 (P<0.05)。与对照组比较，观察组患者强化期结束时和疗程结束时CD3+、CD4+水平及CD4+/CD8+升高（P<0.05）；2组患者强化期结束时和疗程结束时CD8+水平比较差异无统计学意义（P>0.05）。结论　芪甲利肺胶囊辅助治疗复治肺结核合并2型糖尿病能提高痰菌转阴率、病灶显效率和空洞闭合率，并能提高中医证候疗效和细胞免疫功能。
Abstract:
Objective　To discuss the auxiliary curative effect of Qijialifei capsule for the treatment of recurrent pulmonary tuberculosis with type 2 diabetes and the changes of T lymphocyte subsets.Methods　Two hundred and eighty recurrent pulmonary tuberculosis with type 2 diabetes patients who were diagnosed definitely by bacteriology were divided into observation group and control group according to admission order,with 140 cases in each group.The two groups were given antituberculosis therapy with 3HRZES/9HRE(H：isoniazid，R：rifampicin，Z：pyrazinamide，E：ethambutol，S：streptomycin).Based on this,the patients in the observation group were added Qijialifei capsule orally for auxiliary treatment,three times a day,three pills each time,the course of treatment was eight months.Sputum negative conversion,lesions and cavity changes,effect of traditional Chinese Medicine syndrome(TCM) and cellular immune function between the two groups were compared.Results　The rate of sputum negative conversion at the end of the intensive phase and the end of the treatment in the observation group was 73.72% (101/137) and 91.24% (125/137),respectively,while in the control group it was 57.97% (80/138) and 80.43% (111/138),the rate of sputum negative conversion at the end of the intensive phase and the end of the treatment in the observation group was higher than that in the control group (P<0.05).The excellence rate of lesions resorption at the end of the intensive phase and the end of the treatment in the observation group was 68.62％(94/137) and 87.59％(120/137),respectively,while in the control group it was 5.65％(63/138) and 69.57％(96/138)，the excellence rate of lesions resorption at the end of the intensive phase and the end of the treatment in the observation group was higher than that in the control group (P<0.05).The synizesis rate of cavity at the end of the intensive phase and the end of the treatment in the observation group was 21.9％(30/137) and 54.01％(74/137),respectively,while in the control group it was10.87％(15/138) and 28.26％(39/138)，the synizesis rate of cavity at the end of the intensive phase and the end of treatment in the observation group was higher than that in the control group (P<0.05).The total effective rate of TCM syndrome at the end the treatment in the observation group and control group was 89.78％(123/137) and 79.71％(110/138),respectively；the total effective rate of TCM syndrome at the end of the treatment in the observation group was higher than that in the control group(P<0.05).Compared with the control group,CD3+,CD4+,CD4+/CD8+ in the observation group at the end of the intensive phase and the end of the treatment were higher（P<0.05）.There was no significant difference in CD8+ at the end of the intensive phase and the end of the treatment between the two groups(P>0.05).Conclusion　Qijialifei capsule in adjuvant treatment of treating recurrent pulmonary tuberculosis with type 2 diabetes can improve the sputum negative conversion rate,excellence rate of lesions resorption and cavity closure rate,and also can improve TCM syndrome efficacy and cellular immune function.

参考文献/References:

［1］　唐神结，高文.临床结核病学［M］.北京：人民卫生出版社，2011：652-655.
［2］　中华医学会结核病学分会.肺结核诊断和治疗指南［J］.中华结核和呼吸杂志，2001，24(2)：70-74.
［3］　沈蕾，裴育，巴建明.2014 ADA糖尿病指南要点解析［J］.中国药物应用与监测，2015,12(1)：7-10.
［4］　方勇，肖和平，周勤琦，等.芪甲利肺胶囊辅助治疗初治肺结核的回顾性分析研究［J］.中国防痨杂志，2014，36(3)：184-188.
［5］　中华医学会.临床诊疗指南·结核病分册［M］.北京：人民卫生出版社，2005：86.
［6］　中华人民共和国国家中医药管理局.中华人民共和国中医药行业标准：中医病证诊断疗效标准［M］.北京：中国医药科技出版社，2012：4-5.
［7］　郑筱萸.中药新药临床研究指导原则(试行)［M］.北京：中国医药科技出版社，2002：390-392.
［8］　周伸瑛.中医内科学［M］.北京：中国中医药出版社，2003：108-113.
［9］　曹志红，程小星，王心静，等.肺结核患者CD4+记忆T细胞亚群的检测分析［J］.实用医学杂志，2009，25(17)：2845-2848.
［10］　王江峰，史玫.硫辛酸联合前列地尔治疗2型糖尿病早期下肢血管神经病变疗效观察［J］.新乡医学院学报，2015，32（12）：1128-1131.
［11］　BARCELOS W，MARTINS-FILHO O A，GUIMARAES T M，et al.Peripheral blood mononuclear cells immunophenotyping in pulmonary tuberculosis patients before and after treatment［J］.MicrobiolImmunol，2006，50(8)：597-605.
［12］　马晓平，马晓红，马晓光，等.芪甲利肺胶囊治疗肺结核310例临床观察报告［J］.中华中医药杂志，2006，21(5)：275-276.
［13］　赵霞，赵烨，朱国强.中药在治疗肺结核中的作用及地位［J］.实用中医内科杂志，2005，19(6)：506-507.
［14］　席秀娥，李明瑛，王霞，等.芪甲利肺胶囊辅助治疗复治肺结核的疗效及安全性观察［J］.中国防痨杂志，2014,36（11）：948-952.

相似文献/References:

[1]程广新. 36例难治肺结核临床分析[J].新乡医学院学报,1987,4(04):044.
[2]范素莲,卫风谦,高建彬,等.243例难治性肺结核耐药的分析[J].新乡医学院学报,1992,9(04):299.
[3]曹青山,王改,郭悦鹏,等.活动性肺结核痰ATBAB检测的临床研究[J].新乡医学院学报,1994,11(02):144.
[4]范素莲,卫凤谦,郭磊,等.难治性肺结核与初治性肺结核耐药性测定[J].新乡医学院学报,1994,11(04):344.
[5]郭磊,马娟玫,王民合,等.Ⅲ型结核病结核菌株原发耐药性测定[J].新乡医学院学报,1996,13(04):374.
[6]郭磊,马娟玫,王民合,等.Ⅲ型结核病结核菌株原发耐药性测定[J].新乡医学院学报,1996,13(04):374.
[7]马永昌　丁卫民　王永亮.增免灵对活动性肺结核患者的疗效及外周血T 淋巴细胞亚群的影响[J].新乡医学院学报,1999,16(04):328.
[8]李振魁,牛俊梅.下叶肺结核48例误诊分析[J].新乡医学院学报,2002,19(05):398.
[9]陈玲.肺结核并发糖尿病患者经强化治疗后痰菌阳性的相关因素分析[J].新乡医学院学报,2012,29(12):942.
[10]韩　伟,崔泰震,黄　健,等.胸腺肽联合抗结核药物治疗耐多药肺结核的临床疗效[J].新乡医学院学报,2015,32(12):1106.

更新日期/Last Update: 2016-10-05